We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $931M
1-Year Est. Return 41.63%
This Fund
S&P 500
This Quarter Est. Return
+6.45%
1 Year Est. Return
+41.63%
3 Year Est. Return
+181.18%
5 Year Est. Return
+113.34%
10 Year Est. Return
+1,823.73%
AUM
$3.23B
AUM Growth
+$1.54B
Cap. Flow
+$1.36B
Cap. Flow %
42.13%
Top 10 Hldgs %
68.77%
Holding
142
New
24
Increased
22
Reduced
20
Closed
25

Top Buys

Rank Stock Value
1
CAVA icon
CAVA Group
CAVA
+$1.32B
2
LXRX icon
Lexicon Pharmaceuticals
LXRX
+$73.7M
3
SLRN
ACELYRIN
SLRN
+$37.2M
4
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$21.3M
5
MORF
Morphic Holding, Inc. Common Stock
MORF
+$17M

Top Sells

Rank Stock Value
1
WW
WW International
WW
+$61.1M
2
ONC
BeOne Medicines Ltd
ONC
+$20.5M
3
FATE icon
Fate Therapeutics
FATE
+$14.8M
4
APLS
Apellis Pharmaceuticals
APLS
+$14.3M
5
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
+$13.1M

Sector Composition

Rank Sector Weight
1 Healthcare 54.66%
2 Consumer Discretionary 41.39%
3 Miscellaneous 3.23%
4 Technology 0.24%
5 Financials 0.2%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GOOGL icon
101
Alphabet (Google) Class A
GOOGL
$4.2T
$479K 0.01%
+4,000
New +$460K
INKT icon
102
MiNK Therapeutics
INKT
$58.9M
$479K 0.01%
22,822
-6,137
-21% -$123K
CRBU icon
103
Caribou Biosciences
CRBU
$139M
$448K 0.01%
105,347
– –
BMRN icon
104
BioMarin Pharmaceuticals
BMRN
$12.4B
$436K 0.01%
5,028
-26,939
-84% -$2.54M
SQZ
105
DELISTED
SQZ Biotechnologies Company
SQZ
$434K 0.01%
1,606,309
– –
LVTX
106
DELISTED
LAVA Therapeutics
LVTX
$406K 0.01%
200,000
– –
HIPO icon
107
Hippo Holdings
HIPO
$851M
$397K 0.01%
24,000
– –
KNTE
108
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
$379K 0.01%
125,000
– –
BEAM icon
109
Beam Therapeutics
BEAM
$2.4B
$350K 0.01%
10,975
– –
STER
110
DELISTED
Sterling Check Corp. Common Stock
STER
$307K 0.01%
+25,000
New +$300K
PCOR icon
111
Procore
PCOR
$8.17B
$293K 0.01%
+4,500
New +$265K
CFG icon
112
Citizens Financial Group
CFG
$29.5B
$261K 0.01%
10,000
+5,000
+100% +$138K
ARWR icon
113
Arrowhead Research
ARWR
$10.3B
$194K 0.01%
5,440
-20,733
-79% -$715K
ALNY icon
114
Alnylam Pharmaceuticals
ALNY
$32.4B
$178K 0.01%
+936
New +$186K
KA
115
DELISTED
Kineta, Inc. Common Stock
KA
$80K ﹤0.01%
31,055
– –
SNTI icon
116
Senti Biosciences Holdings
SNTI
$9.65M
$35K ﹤0.01%
5,556
– –
PLRX icon
117
Pliant Therapeutics
PLRX
$70.6M
$27K ﹤0.01%
1,490
-253,595
-99% -$6M
AIG icon
118
American International
AIG
$39.5B
– –
-4,000
Closed -$201K
ANNX icon
119
Annexon
ANNX
$726M
– –
-1,018,303
Closed -$3.92M
ARVN icon
120
Arvinas
ARVN
$547M
– –
-18,108
Closed -$495K
BAC icon
121
Bank of America
BAC
$416B
– –
-8,000
Closed -$229K
BBIO icon
122
BridgeBio Pharma
BBIO
$13.3B
– –
-500,000
Closed -$8.29M
BCRX icon
123
BioCryst Pharmaceuticals
BCRX
$2.06B
– –
-67,909
Closed -$566K
ETNB
124
DELISTED
89bio
ETNB
– –
-500,000
Closed -$7.62M
FATE icon
125
Fate Therapeutics
FATE
$279M
– –
-2,600,000
Closed -$14.8M
2 3 4
5
6

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $931M AUM 47.97% 1-Year Est. Return
ACM
Ashe Capital Management Englewood Cliffs, New Jersey $931M AUM 4.95% 1-Year Est. Return
SAM
Sycomore Asset Management Paris, France $932M AUM 51.25% 1-Year Est. Return
NS
Night Squared New York $930M AUM 56.46% 1-Year Est. Return
PA
Planning Alternatives Birmingham, Michigan $933M AUM 28.32% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $933M AUM 56.2% 1-Year Est. Return
CICI
Capital Investment Counsel Inc Raleigh, North Carolina $929M AUM 53.07% 1-Year Est. Return
CAM
Claret Asset Management Montreal, Quebec, Canada $928M AUM 25.4% 1-Year Est. Return

Artal Group's Q2 2023 Portfolio in Review

As of Q2 2023, Artal Group held 142 positions worth $3.23B, up 92% from $1.68B the previous quarter. Its ten largest holdings account for 69% of the portfolio.

Artal Group deployed $1.36B of net new capital in Q2 2023, opening 24 new positions and adding to 22 existing holdings. Its largest new stake was CAVA Group: 32,007,990 shares worth $1.31B.

By sector, the portfolio is most concentrated in Healthcare at 55% of assets, down from 94% a quarter earlier, followed by Consumer Discretionary and Miscellaneous.

On the sell side, the largest reduction was BeOne Medicines Ltd, an estimated $20.5M trimmed.

  • Artal Group's largest Q2 2023 buy was CAVA Group: 32,007,990 shares worth $1.31B.
  • Artal Group added most to Lexicon Pharmaceuticals in Q2 2023, an estimated $73.7M increase.
  • Artal Group's biggest Q2 2023 reduction was BeOne Medicines Ltd, cutting an estimated $20.5M.
  • Artal Group fully exited WW International in Q2 2023, selling an estimated $61.1M.
  • Artal Group's ten largest holdings make up 69% of its $3.23B portfolio in Q2 2023.
  • Artal Group opened 24 new positions and closed 25 in Q2 2023.
  • Artal Group's portfolio value rose 92% quarter-over-quarter to $3.23B.

Based on Artal Group's 13F filing for Q2 2023, filed 11 Aug 2023.